Idec Australia

Biogen, formerly known as Biogen Idec, is a global biopharmaceutical leader specializing in therapies for neurological and neurodegenerative diseases. The company's Australian operations, Biogen Australia, focus on providing access to innovative treatments for conditions such as Multiple Sclerosis (MS), Spinal Muscular Atrophy (SMA), and Alzheimer's disease. Biogen is recognized for pioneering the development of monoclonal antibodies and antisense oligonucleotides, including the first approved treatment for SMA, Spinraza. Following the 2003 merger between Biogen and IDEC Pharmaceuticals, the company operated as Biogen Idec before rebranding to Biogen in 2015. Today, the company maintains a robust pipeline targeting high-unmet-need areas like Amyotrophic Lateral Sclerosis (ALS) and Friedreich's ataxia. Biogen Australia plays a critical role in local clinical research and patient support programs across the Oceania region.